Bipolar Radiofrequency Ablation Treatment for Benign Prostatic Hyperplasia: A Retrospective Study of Efficacy and Safety in High-Risk Patients
Abstract
BACKGROUND
Benign prostatic hyperplasia (BPH) is a common condition, particularly among high-risk patients who are unsuitable for surgical intervention due to comorbidities or anticoagulant use. Bipolar radiofrequency ablation is a minimally invasive technique that has been studied for its potential safety and efficacy. This study aimed to investigate the effectiveness of bipolar radiofrequency ablation in treating BPH and to identify the factors influencing the procedural success in high-risk patients.
METHODS
Forty-six patients who underwent radiofrequency ablation treatment for prostate between 2018 and 2022 were included in this study. Pre-procedure prostate volume, International Prostate Symptom Score (IPSS), post-voiding residual urine volume (PVR), maximum urine flow rate (Qmax) on uroflowmetric examination, quality of life (QoL) due to urinary symptoms, metabolic syndrome status and bladder wall thickness on ultrasonographic examination were measured and compared with the values at the 3rd month of follow-up.
RESULTS
The mean age of the patients was 75.34 ± 10.67 years (55-94 years). Qmax, PVR, QoL and IPSS improved in all the patients after the procedure (p < 0.001). High pre-procedure PVR, low pre-procedure Qmax and prostate volume less than 70 g were found to be statistically significant factors affecting the success of the procedure (p = 0.03, 0.03, 0.04) (odds ratio (OR) = 1.15, 0.75, 1.30).
CONCLUSIONS
Bipolar radiofrequency ablation for prostate is a safe…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.